Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:25:27.095Z.
Calculation as of: 2026-10-06T13:25:27.095Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d88ebff11657cb0645ea93f74423bc241bf41286751ec96f31399ab1bd3406dc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Aprea Therapeutics, Inc.
Market Cap
$8.37M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $8.37M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.76M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.77M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $9.09M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.64M | N/A |
| HeartSciences Inc. (HSCS)vs › | $9.42M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
| Jasper Therapeutics, Inc. (JSPR)vs › | $9.63M | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
